Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States

Maximilian Salcher‐Konrad(London School of Economics and Political Science), Courtney Davis(King's College London)
Milbank Quarterly
October 6, 2020
10.1111/1468-0009.12476
Cited by 87

Related Papers

Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis
|BMJ|2019|242
Generating comparative evidence on new drugs and devices before approval
|The Lancet|2020|80